Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection

Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their a...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 11; no. 22; p. 6745
Main Authors Fazzini, Luca, Caggiari, Ludovica, Deidda, Martino, Onnis, Carlotta, Saba, Luca, Mercuro, Giuseppe, Cadeddu Dessalvi, Christian
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 15.11.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their attention on studying the metabolic profile, first in animals, and, subsequently, in humans, looking for profiles which could be able to predict drug-induced cardiotoxicity and cardiovascular damage. In clinical practice, patients identified as being at risk of developing cardiotoxicity undergo a close follow-up and more tailored therapies. Injury to the heart can be a consequence of both new targeted therapies, such as tyrosine kinase inhibitors, and conventional chemotherapeutic agents, such as anthracyclines. This review aims to describe all of the studies carried on this topic of growing interest.
Bibliography:These authors share the first authorship.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11226745